# Coherus Oncology, Inc. (CHRS)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/CHRS/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 26.62M | $ -58.57M | $ -177.86M | $ 37.71M | $ 60.84M |
| 2025 | $ 43.18M | $ -174.36M | $ -141.83M | $ 40.34M | $ 61.01M |
| 2024 | $ 202.02M | $ 29.96M | $ -21.48M | $ 269.90M | $ -131.99M |
| 2023 | $ 278.15M | $ -257.22M | $ -189.40M | $ 480.84M | $ -193.43M |
| 2022 | $ 235.76M | $ -325.92M | $ -271.64M | $ 480.42M | $ -137.42M |
| 2021 | $ 388.16M | $ -341.26M | $ -46.03M | $ 419.02M | $ 97.73M |
| 2020 | $ 606.17M | $ 168.47M | $ 187.16M | $ 417.10M | $ 280.97M |
| 2019 | $ 459.60M | $ 115.95M | $ 34.25M | $ 188.64M | $ 105.21M |
| 2018 | $ 0 | $ -276.47M | $ -211.38M | $ 103.09M | $ -38.59M |
| 2017 | $ 2.10M | $ -320.85M | $ -275.97M | $ 101.41M | $ 30.54M |
| 2016 | $ 261.55M | $ -175.19M | $ -356.42M | $ 100.26M | $ 19.35M |
| 2015 | $ 42.18M | $ -313.47M | $ -160.28M | $ 0 | $ -6.93M |
| 2014 | $ 43.95M | $ -123.12M | $ -37.83M | $ 0 | $ 66.76M |
| 2013 | $ 3.91M | $ -76.28M | $ 21.40M | $ 4.20M | $ -42.38M |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 0.62 |
| Liabilities / Eq | 2.14 |
| Current Ratio | 1.77 |

## Other views

- [Metrics](https://sponda.capital/en/CHRS.md)
- [Charts](https://sponda.capital/en/CHRS/charts.md)
- [Compare](https://sponda.capital/en/CHRS/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-29.